Targeted intensification by a new preparative regimen for patients with low-grade B-cell lymphoma utilizing standard-dose yttrium-90 ibritumomab tiuxetan [ibritumomab tiuxetan Y-90] (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM [carmustine + etoposide + cytarabine + melphalan] followed by autologous stem cell transplantation (ASCT).

Trial Profile

Targeted intensification by a new preparative regimen for patients with low-grade B-cell lymphoma utilizing standard-dose yttrium-90 ibritumomab tiuxetan [ibritumomab tiuxetan Y-90] (Zevalin) radioimmunotherapy (RIT) combined with high-dose BEAM [carmustine + etoposide + cytarabine + melphalan] followed by autologous stem cell transplantation (ASCT).

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2012

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Autologous stem cell therapy; Carmustine; Cytarabine; Etoposide; Melphalan
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Jun 2012 Updated two-year overall survival data presented at the 17th Congress of the European Haematology Association, according to a Spectrum Pharmaceuticals media release.
    • 07 Sep 2006 Additional lead trial center and investigator identified as reported by ClinicalTrials.gov.
    • 04 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top